panCELLa Inc. and its subsidiary, Implant Therapeutics, are pleased to announce their partnership with Angios Biotech to evaluate the efficacy of our technologies as incorporated into allogeneic vascular transplants deri...
Recently published (27 May 2021) in Nature Communications, a highly respected peer-reviewed scientific journal: Human stem cells harboring a suicide gene improve the safety and standardisation of neural transplants i...
"Hiding therapeutic cells (hypoimmunogenic or immune cloaked) from the immune system is intrinsically risky. Therefore, the development and use of these cells have to contain a system that replaces the missing tumour sur...
panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics. Implant Therapeutics, under the guidance of D...
Licenses aim to accelerate drug discovery leading to development of new therapies PanCELLa agreement marks MilliporeSigma’s first CRISPR license for bioproduction “MilliporeSigma’s latest CRISPR licenses are th...
The inventors of panCELLa's exclusive induced Allogeneic Cell Tolerance have recently published a letter in CellStemCell. This letter is in response to Bryan J. González, et. all's "How Safe Are Universal Pluripotent...
New iPSC Master Cell Banks to Accelerate Development of Novel Cell Therapies panCELLa and CCRM collaborate to benefit academia and industry April 21, 2020, (Toronto, ON) -- Toronto-based panCELLa and CCRM have exec...
panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and develo...
panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients...
EVOTEC LICENSES PANCELLA’S STATE-OF-THE-ART IPSC TECHNOLOGies iACT STEALTH CELL™ AND FAILSAFE™ FOR USE IN CELL THERAPY ACCESS TO PANCELLA’S TECHNOLOGY HAS THE POTENTIAL TO ENABLE SAFE AND OFF-THE-SHELF CELL TH...